We evaluated a novel psoralen-inactivated dengue virus type 1 (DENV-1) vaccine candidate in Mus musculus mice. Mice received intradermal alum or 5 to 10 ng of psoralen-inactivated virus. Anti-DENV-1 neutralizing antibody was detectable in 10/11 mice receiving a 10-ng dose at 90 days. Psoralen-inactivated DENV-1 is immunogenic in mice.
We evaluated a novel psoralen-inactivated dengue virus type 1 (DENV-1) vaccine candidate in Mus musculus mice. Mice received intradermal alum or 5 to 10 ng of psoralen-inactivated virus. Anti-DENV-1 neutralizing antibody was detectable in 10/11 mice receiving a 10-ng dose at 90 days. Psoralen-inactivated DENV-1 is immunogenic in mice.
Dengue viruses consist of four distinct RNA viruses of the genus Flaviviridae and are transmitted to humans primarily through the bite of the Aedes aegypti mosquito. Prior dengue virus infection is a major risk factor for the subsequent development of dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) following reinfection with a heterotypic dengue virus serotype. Dengue virus vaccine development has thus been hindered by the competing needs to develop a vaccine that provides lasting and uniform protection against all four serotypes without predisposing recipients to an increased risk of DHF and DSS.
Psoralens are photoreactive compounds that freely permeate phospholipid membranes and intercalate between nucleic acids. Following exposure to UV-A radiation, the intercalated psoralen covalently cross-links pyrimidine residues, leading to viral inactivation through the inhibition of genome replication. The interaction of psoralen with viral nucleic acids leaves immunogenic surface epitopes intact (4) .
In this study, we photoinactivated the dengue virus type 1 (DENV-1) Western Pacific 74 strain with three different psoralens: 4'-aminomethyltrioxsalen hydrochloride (AMT; product number A4330, CAS number 62442-61-9; Sigma-Aldrich), 8- Mouse inoculation. Three groups of seven study-na'ive, adult Swiss-Webster outbred Mus musculus mice and one group of four mice were selected from the Naval Medical Research Center Detachment (NMRCD) mouse colony. All mice were 30 g or greater in mass. All procedures were conducted in accordance with protocols approved by the NMRCD Institutional Animal Care and Use Committee. Injections and blood sampling were performed by trained personnel who injected ketamine (100 mg!ml), acepromazine (5 mg!ml), and xylazine (20 mg!ml) intraperitoneally at a starting dose of 0.1 ml/100 g body mass. Group A (seven mice) received 0.05 ml of AMT-DENV-1 (5 ng), which was injected intradermally into the tail on days 0, 14, and 28. Group B (seven mice) received 0.1 ml of AMT-DENV-1 (10 ng) injected on days 0, 14, and 28. Group C (four mice) received 0.1 ml of AMT-DENV-1 (10 ng) injected on days 0, 28, and 60. Control animals (seven mice) received injections of 10% Alhydrogel and phosphate-buffered saline on days 0, 14, and 28. Blood samples were obtained from the retro-orbital sinus of the mice while they were under anesthesia on days 0, 14, 28, 60, and 90. Sera were assayed for anti-DENY antibodies by an IgG enzyme-linked immunosorbent assay (ELISA) and a 50% plaque reduction neutralization test (PRNTs 0 ) (9) .
All mice were seronegative for anti-DENV-1 antibodies by "DENY-I was inactivated hy cxposu r~ to UV-A at two intensities and three uiiTercnt ps<lfnlcn cornpnunus. lnactivati nn was mmt efficient with UV-A at I,OfXI JLW/crn 2 in combination with lf1 1 ,giml of AMT. DENY-I Western Pacitic 74 was used at a titer of 3.4 x Ill' Pf'U/mlto infect Vern· 7/C6/36·1 IIMll/06 cells. The volume of DENY-I and the compound was S ml in a 5(}.mm dish. l'soralen was used at a finn I C {)OCcntrution of 10 tLg/ml. Ccntri·<cp columns (catalog number CS-!10 1; l'rinccton Scparatoon) were used for DENY-I purificatonn (for each treatme nt).
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ELISA and PRNT 50 at the baseline. Anti-DENY-1 lgG was detectable in all vacc inated mice following the adm inistration of two doses (on day 28 for groups A and B, on day 60 for group C). !gO remained detectable in seven of seve n mice in group Band four of four mice in group Cat day 90 (30 days after the administration of the third vaccine dose in this group), but only live of seven mice in group A had detectable lgG at day 60 and five of six mice in group A had detectable I gO at day 90 (following the death of one mouse between days 60 and 90). The PRNT 50 results arc shown in Fig. I . Although lgG was detect ab le by the anti -DENY-! ELISA in more group B mice than group A mice at YO days, the geometric mean PRNT 50 titers were slightly higher in group A mice. T he PRNT 50 titers were slower to rise in the mice in group C but were higher than those in the other groups at any ot her time point at 90 days {30 days after the last vacci ne dose for group C versus 60 days for groups A and B).
Anli-DENY-1 lgG was undetectable in all control mice throughout the experiment , with the PRNT 50 tit ers being < 1:40 in all seven study mice at all time poi nts. Conclusions. On the basis of our findings, AMT-inactivated DENY-I is immunoge nic in Mus musculus mice. Psoraleninactiva tcd viruses should retain their three-d imensional st ruc· turc, permitting the developmen t of antibodies to multiple epitopcs tha t may partici pate in immunity. Psorale ns freely permeate through lipid bilayers and do not appear to interact with proteins. Additiona lly, they induce the cross-link ing of pyrimid ines only following UY exposu re (5, 6) . This featu re of psoralcns has made them attractive in transfus ion medicine for pathogen inactivat ion ( I. 7. II), particularly th e usc of amoto· salcn as an altern ative to traditional leukocyte red uction methods fo r the prevention of parvovirus ( I) and cytomegalovirus (10) transmission.
Psoralens may have adva ntages over formalin as a mode of viral inactivation. Formalin modi li es vi ral epi topes through the addition of carbonyl groups, which has been suggested to be a mechanism for the hyperse nsitiv ity to natural infection seen after the ad ministration of a fo rmalin-in activa ted respi ratory syncytial virus vaccine {8). Disease outbreaks due to incom· pletc formalin inact ivation have also been reported {2, 3).
Several questions remain fo llowin g this pilot study. T he wan- ing of antibody titers in treated mice over 90 days suggests that this particular formulation may benefit from strategies to augment its response (e.g., through the use of different adjuvants, higher vaccine doses, or alternate routes of administration). The efficacy of our strategy against DENV-2, DENV-3, and DENY -4 remains to be demonstrated, as does the immunogenicity of a tetravalent formulation. Testing with nonhuman primates will provide additional data about the necessary dose and duration of the serological response, as well as immunity following in vivo dengue virus challenge. Further study of psoraJen inactivation is warranted for dengue vaccine development.
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